Our platform integrates automated systems to enable scalable and cost-effective manufacture of viral vectors.
Manufacturing viral vectors is time consuming and highly variable.
Oxford Biomedica has invested in system automation to streamline production, minimise process risks and reduce costs. Our automated systems enable faster cell line screening as well as highly efficient process development and analytical testing. We have partnered with innovative companies to automate time-consuming experiments and lab workflows, simplify data analysis, and ensure complete traceability and repeatability.
Our investment in automation has improved the quality, reproducibility, and robustness of our processes.